Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective.
about
Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromesWorld health dilemmas: Orphan and rare diseases, orphan drugs and orphan patientsA Review on Iron Chelators in Treatment of Iron Overload SyndromesOpportunity cost of funding drugs for rare diseases: the cost-effectiveness of eculizumab in paroxysmal nocturnal hemoglobinuriaOral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.Advances in iron chelation: an update.Cost utility analysis of reduced intensity hematopoietic stem cell transplantation in adolescence and young adult with severe thalassemia compared to hypertransfusion and iron chelation program.Iron-chelating therapy for transfusional iron overloadThe role of galenic innovation in improving treatment compliance and persistence: three case studies.Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.What is new in iron overload?Iron overload in myelodysplastic syndromes.Cost analysis of iron-related complications in a single institute.Prevention of β Thalassemia in Northern Israel - a Cost-Benefit AnalysisIron overload in myelodysplastic syndromes: diagnosis and management.Iron overload and allogeneic hematopoietic stem-cell transplantation.Pharmacoeconomic considerations in treating iron overload in patients with β-thalassaemia, sickle cell disease and myelodysplastic syndromes in the US: a literature review.Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study.Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia.Cost-utility of chelators in transfusion-dependent β-thalassemia major patients: a review of the pharmacoeconomic literature.Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia.Management of iron overload in hemoglobinopathies: what is the appropriate target iron level?Iron chelation in thalassemia: time to reconsider our comfort zones.Update on the use of deferasirox in the management of iron overload.Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes.Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients.Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1-2):1-15.].Hydroxyurea for hemoglobin E/β-thalassemia: a systematic review and meta-analysis.Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective.Hydroxyurea for lifelong transfusion-dependent β-thalassemia: A meta-analysis.Screening for hemosiderosis in patients receiving multiple red blood cell transfusions.Bayesian estimates of the prevalence of β-thalassemia trait in voluntary blood donors of central India: a survey.Quality of life in patients with transfusion-dependent thalassemia after hematopoietic SCT.
P2860
Q26771519-1CEEDDFE-79C1-42EF-81A0-D2447718009DQ26826936-B120D2EE-9035-4E90-A3D6-F1672053ABCBQ28067212-F973FE19-CA17-4AC3-9F56-AA6D6597B240Q28243221-2D827CF4-9BA1-4B79-9596-D7B8B6A85F1EQ31037298-0CDB6896-DAB9-4144-BADA-969C03BB28DCQ34174307-44230F13-AA13-4814-9111-22DA7C525082Q34573919-2EF14B25-9CE9-4437-8033-4D41BD1C2107Q34806460-19940415-96E9-453E-948A-54417A4DDE36Q35454381-D8567D48-3810-40D5-9ED5-8612E767BD79Q36946007-14E3C59C-5CC8-4B54-AA42-28CF66F309A1Q36953320-E24992C3-C8C3-44BD-8D37-5EF1FEC7A8F4Q37093678-DFEEB6F4-0D62-4BB1-9779-D0BF5F6BDB16Q37205325-01BBAF60-0CEF-4828-AE1A-4B77EB0C35ADQ37663009-FB5FA329-677F-40F5-871E-A6837F60B667Q37686048-8889C359-4394-4515-86E3-38C42C582086Q37842351-ABADACC1-DC1B-4313-8CAD-AA05E071985FQ37859718-586DF9D8-CF34-4B77-91A3-0F186A940AF0Q37882681-68D9D21B-DD73-44D4-87E9-6C0767797E92Q38148200-E3246B94-FE94-43D5-9EAB-A29824469739Q38219425-B436DF45-1D11-4C97-AD98-4710BE6643BFQ38219588-3D5DFA5A-068F-4CE4-B16D-E538EE3EF48AQ38836181-29778F17-81C3-49AB-A793-828CB4A62979Q39782885-AD9B11E4-E6DA-4C94-815D-36624DADD8D1Q42117340-B1FA23FA-0B6E-45B0-B092-F42E4C8C0C06Q43294066-07D1323A-BEC6-451D-8A8F-D69BBC537CD8Q46103118-72268ED9-119E-42AF-8B0A-53611A7A3D7FQ46209130-D6B06283-B6C5-4388-AF69-5F26BE724D9EQ47980084-0252A98F-752A-4F5A-9B09-ADF9F4D12E29Q48379687-81A5A8C4-27A9-466B-AFBF-4C33542CB860Q50027816-1BCBA3EB-9006-4110-923B-78CDD91F9C48Q50217904-79082897-3091-435A-B8D6-BEA6A2065AA1Q51637320-6E7DDA53-FB72-49B3-9241-F5D89E1F5663Q53142347-31181C61-911A-48C0-9708-3CD213AFB595
P2860
Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Cost effectiveness of once-dai ...... healthcare system perspective.
@ast
Cost effectiveness of once-dai ...... healthcare system perspective.
@en
type
label
Cost effectiveness of once-dai ...... healthcare system perspective.
@ast
Cost effectiveness of once-dai ...... healthcare system perspective.
@en
prefLabel
Cost effectiveness of once-dai ...... healthcare system perspective.
@ast
Cost effectiveness of once-dai ...... healthcare system perspective.
@en
P2093
P1433
P1476
Cost effectiveness of once-dai ...... healthcare system perspective
@en
P2093
Jean-Francois Baladi
Oleg Sofrygin
Pradyumna D Phatak
Simu K Thomas
Thomas E Delea
P304
P356
10.2165/00019053-200725040-00005
P577
2007-01-01T00:00:00Z
P6179
1034403563